Siamycin I  (Synonyms: BMY-29304)

Siamycin I (BMY-29304), a 21-residue tricyclic peptide, is a secondary metabolite in actinomycetes. Siamycin I is a HIV fusion inhibitor with ED₅₀s of 0.05 to 5.7 μM for acute HIV type 1 (HIV-1) and HIV-2 infections. Siamycin I inhibits the gelatinase and gelatinase biosynthesis-activating pheromone (GBAP) signaling via the FsrC-FsrA two-component regulatory system in a noncompetitive manner. Siamycin I suppresses the expression of both fsrBDC and gelE-sprE transcripts. Siamycin I, a lasso peptide, interacts with lipid II and inhibits cell wall biosynthesis. Siamycin I, an antibiotic, has the potential for enterococcal infections research^[1][2][3][4].

Siamycin I 浓度为 1 μM 轻微抑制 E. faecalis 的生长 (接种后 5 小时生长 80%)，浓度为 5 μM 时完全抑制生长 (接种后 12 小时无生长)^[3]。
siamycin I (0-1 μM; 24 小时) 在 0.25 μM 浓度下轻微抑制生物膜形成，浓度高于 0.5 μM 时抑制作用显着^[3]。
Siamycin I 抑制 C8166 细胞与慢性感染 HIV 的 CEM-SS 细胞之间的融合 (ED₅₀=0.08 μM)，但对 Sendai 病毒诱导的融合或小鼠成肌细胞融合没有影响^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

2163.48

C₉₇H₁₃₁N₂₃O₂₆S₄

164802-68-0

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Pikyee Ma, et al. Anti-HIV siamycin I directly inhibits autophosphorylation activity of the bacterial FsrC quorum sensor and other ATP-dependent enzyme activities. FEBS Lett. 2011 Sep 2;585(17):2660-4.  [Content Brief]

  [2]. Stephanie Tan, et al. The Lasso Peptide Siamycin-I Targets Lipid II at the Gram-Positive Cell Surface. ACS Chem Biol. 2019 May 17;14(5):966-974.  [Content Brief]

  [3]. Jiro Nakayama, et al. Siamycin attenuates fsr quorum sensing mediated by a gelatinase biosynthesis-activating pheromone in Enterococcus faecalis. J Bacteriol. 2007 Feb;189(4):1358-65.  [Content Brief]

  [4]. M Tsunakawa, et al. Siamycins I and II, new anti-HIV peptides: I. Fermentation, isolation, biological activity and initial characterization. J Antibiot (Tokyo). 1995 May;48(5):433-4.  [Content Brief]